Evaluation and perspective of 20 years of neonatal screening in Galicia. Program results.
Galician newborn screening program for early detection of endocrine and metabolic diseases began in 1978 and was a pioneer in expanded newborn screening in Spain with the incorporation of mass spectrometry in July 2000. As a primary objective, 28 diseases are screened, including those recommended SNS except sickle cell anemia which is in the inclusion phase. In its 20-year history, 404,616 newborns (nb) have been analyzed, identifying 547 cases affected by the diseases included, with a global incidence of 1: 739 newborns and 1: 1.237 of the screened inborn errors of metabolism (IEM) (1:1.580 nb if excluding benign hyperphenylalaninemia-HPA), with an average participation of 99.35%, progressively higher during the analyzed period. Among the pathologies screened, congenital hypothyroidism (1:2.211 nb), cystinuria (1:4.129 nb) and HPA (1:5.699 nb), followed by phenylketonuria and cystic fibrosis (1:10,936 nb) stand out for their incidence. Sixty-six cases of false positives were identified (seventeen of them in relation to maternal pathology) and five false negatives, being the overall PPV and NPV of the program respectively of 89.2% and 99.99%, with a sensitivity of 99.09% and a specificity of 99.98%. The mortality rate of diagnosed CME patients is 1.52%, with eleven cases presenting symptoms prior to the screening result (2%). The intelligence quotient of IEM patients at risk of neurological involvement is normal in more than 95% of cases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:94 |
|---|---|
| Enthalten in: |
Revista espanola de salud publica - 94(2020) vom: 16. Dez. |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Evaluación y perspectiva de 20 años de cribado neonatal en Galicia. Resultados del programa |
|---|
| Beteiligte Personen: |
Sánchez Pintos, Paula [VerfasserIn] |
|---|
| Themen: |
Congenital hypothyroidism |
|---|
| Anmerkungen: |
Date Completed 29.04.2021 Date Revised 29.04.2021 published: Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM318890461 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318890461 | ||
| 003 | DE-627 | ||
| 005 | 20231225170313.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||spa c | ||
| 028 | 5 | 2 | |a pubmed24n1062.xml |
| 035 | |a (DE-627)NLM318890461 | ||
| 035 | |a (NLM)33323918 | ||
| 035 | |a (PII)e202012161 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Sánchez Pintos, Paula |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation and perspective of 20 years of neonatal screening in Galicia. Program results. |
| 246 | 3 | 3 | |a Evaluación y perspectiva de 20 años de cribado neonatal en Galicia. Resultados del programa |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.04.2021 | ||
| 500 | |a Date Revised 29.04.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Galician newborn screening program for early detection of endocrine and metabolic diseases began in 1978 and was a pioneer in expanded newborn screening in Spain with the incorporation of mass spectrometry in July 2000. As a primary objective, 28 diseases are screened, including those recommended SNS except sickle cell anemia which is in the inclusion phase. In its 20-year history, 404,616 newborns (nb) have been analyzed, identifying 547 cases affected by the diseases included, with a global incidence of 1: 739 newborns and 1: 1.237 of the screened inborn errors of metabolism (IEM) (1:1.580 nb if excluding benign hyperphenylalaninemia-HPA), with an average participation of 99.35%, progressively higher during the analyzed period. Among the pathologies screened, congenital hypothyroidism (1:2.211 nb), cystinuria (1:4.129 nb) and HPA (1:5.699 nb), followed by phenylketonuria and cystic fibrosis (1:10,936 nb) stand out for their incidence. Sixty-six cases of false positives were identified (seventeen of them in relation to maternal pathology) and five false negatives, being the overall PPV and NPV of the program respectively of 89.2% and 99.99%, with a sensitivity of 99.09% and a specificity of 99.98%. The mortality rate of diagnosed CME patients is 1.52%, with eleven cases presenting symptoms prior to the screening result (2%). The intelligence quotient of IEM patients at risk of neurological involvement is normal in more than 95% of cases | ||
| 650 | 4 | |a Evaluation Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Congenital hypothyroidism | |
| 650 | 4 | |a Cystic fibrosis | |
| 650 | 4 | |a Inborn errors of metabolism | |
| 650 | 4 | |a Newborn screening | |
| 650 | 4 | |a Sensitivity | |
| 650 | 4 | |a Spain | |
| 650 | 4 | |a Specificity | |
| 700 | 1 | |a Cocho de Juan, José Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Bóveda Fontán, M Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a Castiñeiras Ramos, Daisy E |e verfasserin |4 aut | |
| 700 | 1 | |a Colón Mejeras, Cristóbal |e verfasserin |4 aut | |
| 700 | 1 | |a Iglesias Rodríguez, Agustin Javier |e verfasserin |4 aut | |
| 700 | 1 | |a de Castro López, María José |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso Fernández, José Ramón |e verfasserin |4 aut | |
| 700 | 1 | |a Fraga Bermúdez, José María |e verfasserin |4 aut | |
| 700 | 1 | |a Couce Pico, María Luz |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista espanola de salud publica |d 1998 |g 94(2020) vom: 16. Dez. |w (DE-627)NLM074740377 |x 2173-9110 |7 nnns |
| 773 | 1 | 8 | |g volume:94 |g year:2020 |g day:16 |g month:12 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 94 |j 2020 |b 16 |c 12 | ||